TG THERAPEUTICS, INC. Other Selling, General and Administrative Expense
TG THERAPEUTICS, INC. (TGTX) reported Other Selling, General and Administrative Expense of $62.33 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherSellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- TG THERAPEUTICS, INC. other selling, general and administrative expense for the quarter ending 2026-06-30 was $62.33M, a 43.14% increase year-over-year.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for the quarter ending 2026-03-31 was $73.14M, a 89.04% increase year-over-year.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for the quarter ending 2025-12-31 was $50.73M, a 68.11% increase year-over-year.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for the quarter ending 2025-09-30 was $51.02M, a 53.58% increase year-over-year.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for fiscal 2025 was $183.98M, a 49.68% increase from fiscal 2024.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for fiscal 2024 was $122.92M, a 25.70% increase from fiscal 2023.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for fiscal 2023 was $97.78M, a 52.68% increase from fiscal 2022.
- TG THERAPEUTICS, INC. other selling, general and administrative expense for fiscal 2022 was $64.05M, a 29.51% decline from fiscal 2021.
| Period end | Other Selling, General and Administrative Expense 3 month | Other Selling, General and Administrative Expense 6 month | Other Selling, General and Administrative Expense 9 month | Other Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.33M 10-Q · filed 2026-08-05 | $135.47M 10-Q · filed 2026-08-05 | $186.19M derived: sum of 3 quarters · filed 2026-08-05 | $237.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $73.14M 10-Q · filed 2026-05-06 | $123.87M derived: sum of 2 quarters · filed 2026-05-06 | $174.89M derived: sum of 3 quarters · filed 2026-05-06 | $218.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $50.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $101.75M derived: sum of 2 quarters · filed 2026-02-27 | $145.29M derived: sum of 3 quarters · filed 2026-08-05 | $183.98M 10-K · filed 2026-02-27 |
| 2025-09-30 | $51.02M 10-Q · filed 2025-11-05 | $94.56M derived: sum of 2 quarters · filed 2026-08-05 | $133.25M 10-Q · filed 2025-11-05 | $163.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $43.54M 10-Q · filed 2026-08-05 | $82.23M 10-Q · filed 2026-08-05 | $112.41M derived: sum of 3 quarters · filed 2026-08-05 | $145.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $38.69M 10-Q · filed 2026-05-06 | $68.87M derived: sum of 2 quarters · filed 2026-05-06 | $102.09M derived: sum of 3 quarters · filed 2026-05-06 | $133.91M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $30.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $63.40M derived: sum of 2 quarters · filed 2026-02-27 | $95.22M derived: sum of 3 quarters · filed 2026-02-27 | $122.92M 10-K · filed 2026-02-27 |
| 2024-09-30 | $33.22M 10-Q · filed 2025-11-05 | $65.05M derived: sum of 2 quarters · filed 2025-11-05 | $92.74M 10-Q · filed 2025-11-05 | $117.36M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $31.83M 10-Q · filed 2025-08-08 | $59.52M 10-Q · filed 2025-08-08 | $84.14M derived: sum of 3 quarters · filed 2026-02-27 | $110.64M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $27.69M 10-Q · filed 2025-05-09 | $52.31M derived: sum of 2 quarters · filed 2026-02-27 | $78.81M derived: sum of 3 quarters · filed 2026-02-27 | $102.65M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $24.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $51.12M derived: sum of 2 quarters · filed 2026-02-27 | $74.95M derived: sum of 3 quarters · filed 2026-02-27 | $97.78M 10-K · filed 2026-02-27 |
| 2023-09-30 | $26.50M 10-Q · filed 2024-11-07 | $50.34M derived: sum of 2 quarters · filed 2024-11-07 | $73.17M 10-Q · filed 2024-11-07 | $90.37M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $23.84M 10-Q · filed 2024-08-09 | $46.67M 10-Q · filed 2024-08-09 | $63.87M derived: sum of 3 quarters · filed 2025-03-03 | $74.39M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $22.83M 10-Q · filed 2024-05-06 | $40.03M derived: sum of 2 quarters · filed 2025-03-03 | $50.55M derived: sum of 3 quarters · filed 2025-03-03 | $66.49M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $17.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $27.72M derived: sum of 2 quarters · filed 2025-03-03 | $43.66M derived: sum of 3 quarters · filed 2025-03-03 | $64.05M 10-K · filed 2025-03-03 |
| 2022-09-30 | $10.51M 10-Q · filed 2023-11-06 | $26.46M derived: sum of 2 quarters · filed 2023-11-06 | $46.84M 10-Q · filed 2023-11-06 | $69.88M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $15.94M 10-Q · filed 2023-08-04 | $36.32M 10-Q · filed 2023-08-04 | $59.37M derived: sum of 3 quarters · filed 2024-02-29 | $84.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $20.38M 10-Q · filed 2023-05-08 | $43.42M derived: sum of 2 quarters · filed 2024-02-29 | $68.86M derived: sum of 3 quarters · filed 2024-02-29 | $93.59M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $23.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $48.48M derived: sum of 2 quarters · filed 2024-02-29 | $73.21M derived: sum of 3 quarters · filed 2024-02-29 | $90.86M 10-K · filed 2024-02-29 |
| 2021-09-30 | $25.44M 10-Q · filed 2022-11-09 | $50.16M derived: sum of 2 quarters · filed 2022-11-09 | $67.82M 10-Q · filed 2022-11-09 | $83.97M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $24.73M 10-Q · filed 2022-08-09 | $42.38M 10-Q · filed 2022-08-09 | $58.53M derived: sum of 3 quarters · filed 2023-03-01 | $70.12M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $17.66M 10-Q · filed 2022-05-10 | $33.80M derived: sum of 2 quarters · filed 2023-03-01 | $45.39M derived: sum of 3 quarters · filed 2023-03-01 | $54.01M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $16.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $27.73M derived: sum of 2 quarters · filed 2023-03-01 | $36.35M derived: sum of 3 quarters · filed 2023-03-01 | $41.52M 10-K · filed 2023-03-01 |
| 2020-09-30 | $11.58M 10-Q · filed 2021-11-08 | $20.20M derived: sum of 2 quarters · filed 2021-11-08 | $25.37M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $8.62M 10-Q · filed 2021-08-06 | $13.79M 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $5.17M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $9.50M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |